• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    7/5/23 1:28:59 PM ET
    $ACCD
    $ACST
    $AENT
    $AHI
    Business Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACCD alert in real time by email

    Gainers

    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.
    • iMedia Brands, Inc. (NASDAQ:IMBI) shares climbed 85.7% to $0.2201 after dropping 10% on Monday. iMedia Brands recently announced receipt of second Nasdaq non-compliance notice.
    • LightPath Technologies, Inc. (NASDAQ:LPTH) rose 30% to $1.75.
    • Impel Pharmaceuticals Inc. (NASDAQ:IMPL) shares gained 26% to $1.6001 after the company received US patent for respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for Parkinson's disease
    • GameSquare Holdings, Inc. (NASDAQ:GAME) gained 23.7% to $3.66. Dairy MAX and Gaming Community Network, a GameSquare Holdings' company, announced the "Level Unlocked Tournament."
    • TMC the metals company Inc. (NASDAQ:TMC) rose 21% to $2.36. On June 30, the company received written notice from Nasdaq notifying that it has regained compliance with minimum bid requirement.
    • BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares climbed 19% to $9.40.
    • Inovio Pharmaceuticals, Inc. (NASDAQ:INO) gained 18.3% to $0.5169.
    • Spark Networks SE (NASDAQ:LOV) gained 17.7% to $0.4534.
    • C4 Therapeutics, Inc. (NASDAQ:CCCC) shares gained 17% to $3.3099 after the company announced the FDA cleared its investigational new drug application for CFT8919.
    • Pegasystems Inc. (NASDAQ:PEGA) gained 14% to $55.87. Wedbush upgraded Pegasystems from Neutral to Outperform.
    • Acasti Pharma Inc. (NASDAQ:ACST) rose 13.9% to $0.5946. Acasti announced alignment with the FDA on GTX-104 pivotal Phase 3 safety trial protocol and confirmed planned initiation of STRIVE-ON in aSAH patients in calendar fourth quarter.
    • Wolfspeed, Inc. (NYSE:WOLF) gained 12.7% to $63.97 after the company announced a 10-year silicon carbide wafer supply deal with Renesas Electronics Corporation.
    • Mullen Automotive, Inc. (NASDAQ:MULN) gained 12.5% to $0.1135. The company announced the retention of Chistian Attar to combat naked short selling activities Wednesday morning.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) rose 10% to $13.92. New reports indicate the company reached a settlement with the U.S. Securities and Exchange Commission (SEC).
    • Xos, Inc. (NASDAQ:XOS) rose 9.5% to $0.2416.
    • Opera Limited (NASDAQ:OPRA) gained 9.2% to $23.48.
    • XPeng Inc. (NYSE:XPEV) climbed 8.3% to $15.15. Xpeng sees sharp growth in deliveries during the second half of the year.

    Losers

    • 1847 Holdings LLC (NYSE:EFSH) fell 31.3% to $0.2406 after the company reported pricing of $1.869 million public offering.
    • Fresh Vine Wine, Inc. (NYSE:VINE) fell 29.9% to $0.4067 after jumping around 157% on Monday.
    • Longevity Market Assets LLC (NASDAQ:ABL) shares dipped 23.7% to $8.27 after starting trading on the Nasdaq.
    • Canopy Growth Corporation (NASDAQ:CGC) shares fell 19.4% to $0.4737. Canopy Growth shares gained 52% on Monday after the company announced it completed all conversions pursuant to the $100 million convertible debentures and provided an update to its balance sheet actions taken to date.
    • Gaucho Group Holdings, Inc. (NASDAQ:VINO) dropped 16.6% to $0.5499.
    • Arrival (NASDAQ:ARVL) fell 15.8% to $2.33. Arrival said on Monday that its proposed merger with special purpose acquisition company Kensington Capital Acquisition Corp V has been terminated.
    • Pioneer Power Solutions, Inc. (NASDAQ:PPSI) dropped 15.3% to $8.30.
    • Amneal Pharmaceuticals, Inc. (NYSE:AMRX) fell 14.7% to $2.60 after the company received FDA complete response letter for its IPX203 new drug application for Parkinson's disease.
    • AXT, Inc. (NASDAQ:AXTI) fell 14.5% to $3.00. AXT said Tongmei, its subsidiary in China, expects to proceed to immediately seek permits from the applicable Chinese authorities to export gallium and germanium substrate products.
    • IMAC Holdings, Inc. (NASDAQ:BACK) fell 14.3% to $0.1191 after jumping 26% on Monday. Theralink Technologies and IMAC Holdings recently entered into a merger agreement.
    • Nocera, Inc. (NASDAQ:NCRA) declined 13.9% to $2.36.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) dropped 13.9% to $2.9528.
    • Biofrontera Inc. (NASDAQ:BFRI) fell 13.7% to $9.30. Benchmark maintained Biofrontera with a Buy and lowered the price target from $140 to $18.
    • Cassava Sciences, Inc. (NASDAQ:SAVA) dropped 12.1% to $22.26. The company announced the top-line clinical results from its Cognition Maintenance Study where oral simufilam in patients with mild-to-moderate Alzheimer's slowed cognitive decline.
    • 22nd Century Group, Inc. (NASDAQ:XXII) fell 12% to $3.9350. 22nd Century shares dropped 22% on Monday after the company announced a 1-for-15 reverse stock split.
    • Zuora, Inc. (NYSE:ZUO) dropped 11.9% to $9.84.
    • Biotricity, Inc. (NASDAQ:BTCY) dipped 11.7% to $2.85. HC Wainwright & Co. reiterated Biotricity with a Buy and raised the price target from $2 to $4.
    • Osisko Gold Royalties Ltd (NYSE:OR) fell 11.2% to $13.97.
    • Wabash National Corporation (NYSE:WNC) dropped 10.8% to $23.15 after Raymond James downgraded the stock from Strong Buy to Market Perform.
    • Advanced Health Intelligence Ltd. (NASDAQ:AHI) fell 10% to $5.13. Bank of New York Mellon raised stake in Advanced Health Intelligence from 21.08% to 22.52%.
    • Puyi Inc. (NASDAQ:PUYI) fell 9.6% to $6.02.
    • Alliance Entertainment Holding Corporation (NASDAQ:AENT) fell 9.4% to $2.50. Alliance Entertainment recently reported pricing of public offering and Nasdaq listing.
    • Accolade, Inc. (NASDAQ:ACCD) fell 9.3% to $11.96.
    • Amyris, Inc. (NASDAQ:AMRS) declined 8.5% to $1.07.
    • Butterfly Network, Inc. (NYSE:BFLY) dropped 8.3% to $2.1750.
    • GeoPark Limited (NASDAQ:GPRK) fell 8.2% to $9.05.
    • Compass, Inc. (NYSE:COMP) declined 7.2% to $3.4150.

     

    Now Read This: Bitcoin Drops But Remains Above $30,000; Compound Becomes Top Loser

    Get the next $ACCD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD
    $ACST
    $AENT
    $AHI

    CompanyDatePrice TargetRatingAnalyst
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Compass Inc.
    $COMP
    3/26/2026$14.00Buy
    The Benchmark Company
    XPeng Inc.
    $XPEV
    3/23/2026$19.00Outperform → Neutral
    Macquarie
    BioXcel Therapeutics Inc.
    $BTAI
    3/17/2026$17.00Buy
    Rodman & Renshaw
    Pegasystems Inc.
    $PEGA
    2/12/2026$48.00Equal Weight → Overweight
    Barclays
    LightPath Technologies Inc.
    $LPTH
    1/29/2026$15.00Buy
    Canaccord Genuity
    Compass Inc.
    $COMP
    1/27/2026$14.00Neutral
    Goldman
    Compass Inc.
    $COMP
    1/26/2026$15.00Overweight
    Analyst
    More analyst ratings

    $ACCD
    $ACST
    $AENT
    $AHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    The Benchmark Company initiated coverage on Compass with a new price target

    The Benchmark Company initiated coverage of Compass with a rating of Buy and set a new price target of $14.00

    3/26/26 8:47:49 AM ET
    $COMP
    EDP Services
    Technology

    XPeng downgraded by Macquarie with a new price target

    Macquarie downgraded XPeng from Outperform to Neutral and set a new price target of $19.00

    3/23/26 8:28:29 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    $ACCD
    $ACST
    $AENT
    $AHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pega Helps Federal Government Modernize Legacy IT Systems with Launch of Pega Blueprint for Government

    Newly certified FedRAMP High design tool helps U.S. agencies rapidly transform aging applications for more efficient operations Pegasystems Inc. (NASDAQ:PEGA), The Enterprise Transformation Company™, today announced the launch of Pega Blueprint™ for Government – a FedRAMP High-authorized AI-powered design tool helping U.S. federal agencies modernize applications and workflows used in sensitive government operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407428509/en/This screenshot of the FedRAMP-High-approved Pega Blueprint for Government shows how a government official can redesign their processes into more moder

    4/7/26 9:00:00 AM ET
    $PEGA
    EDP Services
    Technology

    22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

    Company to Pursue Additional PMTA Submissions, Building on Its Status as the Only Holder of an FDA-Authorized Low Nicotine Combustible Cigarette Branded as VLN® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Address Wider Consumer Preference and Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced an update on the advancement of a 100mm VLN® reduced nicotine content cigarette. The Company's proprietary reduced nicotine technology is designed to serve adult smokers who w

    4/7/26 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month. These contributions reflect Amneal's ongoing commitment to expanding access to essential medicines and supporting patient care, education, and advocacy for the Parkinson's community. Every six minutes, someone in the United States is diagnosed with Parkinson's disease, underscoring the growing impact of a condition that affects more than 10 million people worldwide. As the

    4/7/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACCD
    $ACST
    $AENT
    $AHI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Xos Inc.

    SCHEDULE 13G/A - Xos, Inc. (0001819493) (Subject)

    4/6/26 4:46:58 PM ET
    $XOS
    Auto Parts:O.E.M.
    Consumer Discretionary

    SEC Form 8-K filed by Inovio Pharmaceuticals Inc.

    8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

    4/6/26 7:03:10 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Compass Inc.

    DEFA14A - Compass, Inc. (0001563190) (Filer)

    4/3/26 4:38:04 PM ET
    $COMP
    EDP Services
    Technology

    $ACCD
    $ACST
    $AENT
    $AHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $ACCD
    $ACST
    $AENT
    $AHI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 18, 2022 - FDA Alerts the Public to Potentially Contaminated Products from Family Dollar Stores in Six States

    For Immediate Release: February 18, 2022 Today, the U.S. Food and Drug Administration is alerting the public that several categories of FDA-regulated products purchased from Jan. 1, 2021, through the present from Family Dollar stores in Alabama, Arkansas, Louisiana, Mississippi, Missouri and Tennessee may be unsafe for consumers to use. The impacted products originated from the company’s distribution facility in

    2/18/22 8:06:10 PM ET
    $ARVL
    Auto Manufacturing
    Consumer Discretionary

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACCD
    $ACST
    $AENT
    $AHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Stillwell Kenneth

    4 - PEGASYSTEMS INC (0001013857) (Issuer)

    4/3/26 4:02:30 PM ET
    $PEGA
    EDP Services
    Technology

    SEC Form 4 filed by Anderson Kenneth Carl

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    4/3/26 10:45:54 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Grogan Donna Roy

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    4/3/26 10:45:44 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACCD
    $ACST
    $AENT
    $AHI
    Leadership Updates

    Live Leadership Updates

    View All

    Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month. These contributions reflect Amneal's ongoing commitment to expanding access to essential medicines and supporting patient care, education, and advocacy for the Parkinson's community. Every six minutes, someone in the United States is diagnosed with Parkinson's disease, underscoring the growing impact of a condition that affects more than 10 million people worldwide. As the

    4/7/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Critical Minerals Boom: Nickel–Cobalt Market Races Toward $35B+ Valuation

    NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Nickel–cobalt alloys might not sound exciting at first, but they're actually a big deal in modern defense. These materials are used in things like jet engines, missile systems, and naval equipment because they can handle extreme heat and stress without breaking down. That's why governments are starting to treat nickel and cobalt as must-have resources, not just commodities. There's also a growing push to secure supply closer to home, since a lot of global production is concentrated in a few regions—something that makes defense planners (and investors) a bit uneasy.   Active Companies mentioned in the article

    3/31/26 8:45:00 AM ET
    $ALOY
    $MP
    $TMC
    Metal Mining
    Basic Materials

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACCD
    $ACST
    $AENT
    $AHI
    Financials

    Live finance-specific insights

    View All

    Wabash Schedules First Quarter 2026 Earnings Conference Call

    LAFAYETTE, Ind., April 06, 2026 (GLOBE NEWSWIRE) -- Wabash (NYSE:WNC) today announced that it will webcast its quarterly earnings conference call to review and discuss its financial results for the first quarter of 2026 on Friday, May 1, 2026, beginning at 12:00 p.m. ET. The call and an accompanying slide presentation will be accessible on the "Investors" section of Wabash's website, www.onewabash.com, under "Events & Presentations." The conference call will be accessible at the following link: https://events.q4inc.com/attendee/310958583 replay of the call will be available shortly after the conclusion of the presentation. Access to the replay will be available on the "Investors" section

    4/6/26 4:25:00 PM ET
    $WNC
    Construction/Ag Equipment/Trucks
    Industrials

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xos Delivers Third Consecutive Quarter of Positive Operating and Free Cash Flow, Accelerates Platform Expansion Across Vehicles, Powertrains, and Energy Storage

    Delivered first production powertrains for Blue Bird school buses Achieved third consecutive quarter of positive operating cash flow and free cash flow, ending 2025 with $14.0 million in cash — up 28% year-over-year Reduced full-year operating expenses by $14.0 million (28.2% YoY) and cut full-year EBITDA loss by more than half — from $42.2 million to $21.0 million LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ:XOS) ("Xos" or the "Company"), a leading energy storage and fleet electrification solutions provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. Building on a year of disciplined execution and consistent opera

    3/26/26 4:10:00 PM ET
    $XOS
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ACCD
    $ACST
    $AENT
    $AHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LightPath Technologies Inc.

    SC 13G/A - LIGHTPATH TECHNOLOGIES INC (0000889971) (Subject)

    12/13/24 3:18:07 PM ET
    $LPTH
    Semiconductors
    Technology

    Amendment: SEC Form SC 13D/A filed by Xos Inc.

    SC 13D/A - Xos, Inc. (0001819493) (Subject)

    12/9/24 3:57:56 PM ET
    $XOS
    Auto Parts:O.E.M.
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Xos Inc.

    SC 13D/A - Xos, Inc. (0001819493) (Subject)

    12/9/24 3:45:37 PM ET
    $XOS
    Auto Parts:O.E.M.
    Consumer Discretionary